secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-024036
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Q2 2025 net loss $4.1M; CyPath Lung revenue up 62% H1
-----------------------------------------------------------------

- Total revenue $1.3M in Q2 2025 vs $2.4M in Q2 2024, reflecting discontinuation of unprofitable pathology services.
- CyPath Lung testing revenue grew 62% YTD to $323K; monthly tests set records in June and July.
- Net loss $4.1M ($0.17/share) vs $2.1M ($0.19/share) in Q2 2024, increase driven by non-cash warrant remeasurement and offering costs.
- Cash $0.8M at June 30, 2025; completed $3.25M public offering in May 2025 to bolster working capital.
- Appointed Dr. Gordon Downie as CMO; expanded IP portfolio with patents in US, China, Canada, Australia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/0001641172-25-024036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-024036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer